Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Revance Therapeutics, Inc. (Nasdaq: RVNC) announced the issuance of 75,400 inducement restricted stock awards (RSAs) to 15 new employees, with a vesting schedule of four years. This action aims to incentivize the new hires, aligning with NASDAQ Listing Rule 5635(c)(4). Revance focuses on innovative aesthetic and therapeutic products, notably its investigational neuromodulator DaxibotulinumtoxinA for Injection, which has completed Phase 3 trials for glabellar lines and seeks U.S. regulatory approval.

Positive

• Issuance of 75,400 RSAs to attract and retain talent.
• DaxibotulinumtoxinA for Injection has completed Phase 3 trials.
• Products targeted for aesthetic market with potential for significant revenue.

Negative

• None.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced new hire grants totaling an aggregate of 75,400 inducement restricted stock awards (“RSAs”) to 15 employees. The RSAs vest over four years, with 25% of the underlying shares vesting on each of the four anniversaries of the applicable vesting commencement date, subject to the new employee's continued service relationship with Revance through the applicable vesting dates.

The Compensation Committee of Revance’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with NASDAQ Listing Rule 5635(c)(4).

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
RHA resilient hyaluronic acid® and RHA® are trademarks of TEOXANE SA.
BOTOX® is a registered trademark of Allergan, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005213/en/

FAQ

What are the details of the RSAs granted by Revance Therapeutics (RVNC)?

Revance Therapeutics granted 75,400 inducement RSAs to 15 new employees, vesting over four years.

What is DaxibotulinumtoxinA for Injection by Revance (RVNC)?

DaxibotulinumtoxinA is an investigational neuromodulator for wrinkles, completing Phase 3 trials and seeking U.S. approval.

How does Revance's recent stock award impact its employment strategy?

The RSAs are part of Revance's strategy to attract and retain key talent important for its growth.